Healthcare -
Biotechnology - NASDAQ - US
$ 0.7851
1.53 %
$ 37.6 M
Market Cap
-0.53
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Shattuck Labs, Inc.
| Net Income | -75.4 M |
| Depreciation & Amortization | 3.83 M |
| Capital Expenditures | -59 K |
| Stock-Based Compensation | 9.55 M |
| Change in Working Capital | 3.02 M |
| Others | 688 K |
| Free Cash Flow | -60.6 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (75.4) | (87.3) | (101.9) | (45.0) | (36.6) | (24.0) | (7.4) |
| Depreciation & Amortization | 3.8 | 4.0 | 3.1 | 1.4 | 0.6 | 0.5 | 0.3 |
| Deferred Income Tax | 0 | 0 | 0 | 3.0 | 1 K | (0.2) | (0.4) |
| Stock Based Compensation | 9.5 | 6.9 | 6.5 | 5.5 | 1.3 | 0.5 | 0.4 |
| Other Operating Activities | (1.5) | (0.8) | 2.4 | 1.5 | 89 K | 41 K | 2.7 |
| Change in Working Capital | 3.0 | (4.1) | (4.5) | (23.5) | 1.0 | 2.2 | (2.5) |
| Cash From Operations | (60.5) | (81.2) | (94.5) | (57.1) | (33.7) | (21.0) | (6.9) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 59 K | (0.4) | (11.6) | (7.9) | (0.7) | (0.5) | (1.2) |
| Other Items | (8.5) | 111.3 | 61.1 | (2.5) | (145.6) | (3.1) | (28.7) |
| Cash From Investing Activities | (8.5) | 110.9 | 49.4 | (10.4) | (146.3) | (3.6) | (29.9) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.8 | 0.9 | 0.2 | 1.9 | 98.6 | 64 K | 35.1 |
| Cash From Financing Activities | 0.8 | 48.6 | 0.2 | 1.9 | 330.9 | 64 K | 35.1 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (68.2) | 78.2 | (44.9) | (65.6) | 150.9 | (24.6) | (1.7) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (60.6) | (81.6) | (106.1) | (65.0) | (34.4) | (21.4) | (8.1) |